Literature DB >> 7870895

Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.

J E Leysen1, W Gommeren, J Mertens, W H Luyten, P J Pauwels, M Ewert, P Seeburg.   

Abstract

We investigated the ligand binding properties in vitro of two splice variants of the cloned human dopamine D2 receptor (the 443 and 414 amino acids long forms called D2L and D2S, respectively), expressed in 293 human kidney cells, in comparison with those of the dopamine D2 receptors in rat striatum, nucleus accumbens and tuberculum olfactorium. The new radioligand, [125I]2'-iodospiperone, showed a similar high binding affinity (KD:0.056-0.122 nM) for cloned human D2S and D2L receptors and for the D2 receptors in the three rat brain areas. Binding affinities of 25 dopamine antagonists and of 10 dopamine agonists belonging to different chemical classes were measured. The IC50 values of the antagonists were virtually identical in the five preparations: spiperone was the most potent compound (pIC50 approximately 9.9), remoxipride the least potent one (pIC50 approximately 5.7). The agonists showed similar IC50 values for the cloned human D2S and D2L receptors but their affinity for rat brain D2 receptors was 2- to 5-fold higher. Dopamine showed shallow inhibition curves, the high affinity binding was 10-fold lower for the cloned human D2 receptors than for the rat brain D2 receptors. Addition of stable guanosine-5'-triphosphate (GTP) analogues shifted the D2 receptors in the rat brain tissues to the "low" affinity state, the low affinity binding of dopamine was equal to the affinity for the cloned human receptor. None of the dopamine antagonists or agonists could differentiate between the two splice forms of the cloned human D2 receptors or between the D2 receptors in rat striatal and mesolimbic tissues. The lower apparent affinity of some agonists and of dopamine in the absence of stable GTP analogues suggests a less appropriate receptor G-protein coupling for the cloned human D2 receptors expressed in the 293 human kidney cells. Unexpectedly, guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S) reduced the [125I]2'-iodospiperone binding to the D2 receptors by 20-35% in the rat brain tissues and the cloned human D2L receptor, and by 75% to the cloned human D2S receptor. The inhibition in the last case could be prevented partly by submicromolar concentrations of dopamine. The GTP-gamma-S effect is suggested to be due to reduction of disulphide bonds in the receptor. Recent molecular modelling studies indicated an important role of the disulphide bridge between Cys107 at the start of transmembrane domain three and Cys182 in the third extracellular loop, for the binding of dopamine to the D2 receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870895     DOI: 10.1007/bf02246947

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Dopamine receptors in the brain and periphery: "state of the art".

Authors:  P G Strange
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

2.  Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment.

Authors:  P Rogue; A Hanauer; J Zwiller; A N Malviya; G Vincendon
Journal:  Eur J Pharmacol       Date:  1991-06-19       Impact factor: 4.432

3.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

Authors:  K A Neve; R L Neve; S Fidel; A Janowsky; G A Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Cloning of the cDNA and gene for a human D2 dopamine receptor.

Authors:  D K Grandy; M A Marchionni; H Makam; R E Stofko; M Alfano; L Frothingham; J B Fischer; K J Burke-Howie; J R Bunzow; A C Server
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

5.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

Authors:  B Giros; P Sokoloff; M P Martres; J F Riou; L J Emorine; J C Schwartz
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

6.  Cloning and expression of a rat D2 dopamine receptor cDNA.

Authors:  J R Bunzow; H H Van Tol; D K Grandy; P Albert; J Salon; M Christie; C A Machida; K A Neve; O Civelli
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

7.  The major dopamine D2 receptor: molecular analysis of the human D2A subtype.

Authors:  L A Selbie; G Hayes; J Shine
Journal:  DNA       Date:  1989-11

8.  Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells.

Authors:  R Y Kanterman; L C Mahan; E M Briley; F J Monsma; D R Sibley; J Axelrod; C C Felder
Journal:  Mol Pharmacol       Date:  1991-03       Impact factor: 4.436

9.  In vitro evaluation of radioiodinated butyrophenones as radiotracer for dopamine receptor study.

Authors:  I Nakatsuka; H Saji; K Shiba; H Shimizu; M Okuno; A Yoshitake; A Yokoyama
Journal:  Life Sci       Date:  1987-10-26       Impact factor: 5.037

10.  Characterization of anti-peptide antibodies for the localization of D2 dopamine receptors in rat striatum.

Authors:  L D McVittie; M A Ariano; D R Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  7 in total

Review 1.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

2.  Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro.

Authors:  R A Lahti; C A Tamminga; A Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2007-07-06       Impact factor: 3.575

Review 3.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

4.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

5.  Phosphorylation- and voltage-dependent inhibition of neuronal calcium currents by activation of human D2(short) dopamine receptors.

Authors:  N A Brown; G R Seabrook
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

6.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 7.  Survey on the pharmacodynamics of the new antipsychotic risperidone.

Authors:  A A Megens; F H Awouters; A Schotte; T F Meert; C Dugovic; C J Niemegeers; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.